Mechanistically, bevacizumab—a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF)—mediates its anti-neoplastic effects through angiogenesis inhibition, a pathway increasingly recognized as potentially modifiable in PJS-related tumorigenesis. The gene discussed is VEGFA; the disease is Peutz-Jeghers syndrome.